Browse our archive of webinars on pharmaceutical and biomedical research from collaborations between pharmaceutical companies, government, biotechnology companies and academia to create new drug discovery opportunities.
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
The study of a single cell, the fundamental unit of our complex bodies, has become an important field in cellular biology, and researchers are using single-cell analysis to shed new light on...
High-throughput sequencing technology such as RNASeq and whole genome sequencing has enabled deep characterization of health and disease states. Biomarker discovery by these means has only h...
The cancer drug discovery landscape is shifting. While research continues to grow in cost and complexity, the pace of development has never been faster. Biopharmaceutical companies can&rsquo...
Stable cell lines are critical tools of cellular assays in drug discovery and development. Over-expressing cell lines are needed to screen for hits, while functional cell lines are needed fo...
Rapid, accurate estimation of relative ligand affinities offers the potential to allow computational methods to direct drug design and development. Towards this goal we have developed t...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
In recognition of Pancreatic Cancer Awareness Month, join us to explore how cutting-edge technologies are transforming our understanding of pancreatic ductal adenocarcinoma (PDAC), one of th...
The quest for alternatives to animal safety testing has fueled the development, characterization, and validation of many new technologies. There have been advances in cell and tissue models...
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG Binding Protein 2 (MECP2) gene. In mouse models of RTT, deficits in long-term potentiation (LTP) at...
The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes)...
Transcriptomics represents a critical discipline in cancer research, enabling comprehensive mapping of gene expression profiles and the identification of fusion genes implicated in tumor dev...
The continued evolution of precision medicine from the early successes seen in Oncology to other areas of medicine, in particular, Chronic Disease Management, is dependent on the efficient t...
The liver plays a critical role in the metabolism and clearance of more than 70% of marketed drugs. Furthermore, toxicity to the liver is a major reason for preclinical and clinical drug fai...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Preterm birth (PTB) is the leading cause of infant mortality and morbidity worldwide. Both preterm labor and neonatal injuries have been linked to inflammation. Of all mediators of inflammati...
What happens when pharma and flow cores face the same challenge — doing more with less? Join Ryan Duggan (AbbVie) and David Leclerc (President, GLIIFCA) for a balanced discussion on h...
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
Structure based drug design is now well established as a highly efficient approach in pharmaceutical research. The approach uses atomic level detail structures of target proteins, most...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
The path form biomarker discovery to conversion to a clinically useful companion diagnostic test presents many challenges. The talk will outline the regulatory requirements to developing a su...
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders affecting 25% of our global population. 20% of NAFLD patients go on to develop Non-alcoholic steatohepatitis (N...
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
Novel annotated Patient-Derived tumor Xenografts (PDX) propagated in immunodeficient mice and Organoids (PDO) in Matrigel have become essential models to study inter- and intra-tumor heterog...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
